부산대학교 도서관

To purchase or authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1742-1241.2006.01180.x Byline: C. A. THOMAS (1), F. GUERCINI (2), Y-C CHUANG (3), M. B. CHANCELLOR (1) Keywords: Botulinum toxin; prostate; benign prostatic hyperplasia; prostrate cancer; prostatitis Abstract: Summary Recently, botulinum neurotoxin type A (BoNT-A) application in the lower urinary tract has been extended to prostate disorders and we would like to review the literature on the mechanisms of action and clinical efficacy of BoNT-A treatment in the prostate. The information was gathered from MEDLINE, abstracts from recent urological meetings and from personal experience. BoNT has demonstrated promising preliminary results for male prostatic disease and translational research suggests a novel mechanism of action of BoNT in the prostate. It is important to remember that the application of BoNT in the prostate is not approved by the regulatory agencies and caution should be applied until larger randomised clinical studies are completed. Author Affiliation: (1)Department of Urology, University of Pittsburgh, Pittsburgh, PA, USA (2)Department of Urology, University of Perugia, Perugia, Italy (3)Division of Urology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan Article History: Paper received 1 June 2006, accepted 31 August 2006 Article note: Michael B. Chancellor, MD, Professor of Urology, Obstetrics & Gynecology, University of Pittsburgh School of Medicine, 700 LS Kaufmann Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA, Tel.: +1 412 692 4096, Fax: +1 412 692 4081, Email: chancellormb@msx.upmc.edu